Update on pulmonary arterial hypertension pharmacotherapy

被引：27

作者：

Velayati, Arash ^{[1
]}

Valerio, Marcos G. ^{[1
]}

Shen, Michael ^{[1
]}

Tariq, Sohaib ^{[1
]}

Lanier, Gregg M. ^{[1
]}

Aronow, Wilbert S. ^{[1
]}

机构：

[1] New York Med Coll, Westchester Med Ctr, Div Cardiol, Dept Med, Valhalla, NY 10595 USA

来源：

POSTGRADUATE MEDICINE | 2016年 / 128卷 / 05期

关键词：

Pulmonary hypertension; PH; PAH; epoprostenol; nifedipine; diltiazem; amlodipine sildenafil; tadalafil; vardenafil riociguat; guanylate cyclase; nitric oxide; PDE-5i; CTEPH; prostacyclin; cyclic AMP; iloprost; beraprost; selexipag; bosentan; ambrisentan; macitentan; dichloroacetate; trimetazidine; ranolazine; Imatinib; RHO-KINASE INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; RIGHT-VENTRICULAR FUNCTION; CONTROLLED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; LONG-TERM TREATMENT; ADD-ON THERAPY; DOUBLE-BLIND; INHALED ILOPROST; AMBRISENTAN THERAPY;

D O I：

10.1080/00325481.2016.1188664

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pulmonary artery hypertension (PAH) refers to several subgroups of disease in which the mean pulmonary artery pressure (mPAP) is elevated to more than 25 mm Hg, pulmonary artery wedge pressure (PAWP) <= 15 mmHg, and an elevated pulmonary vascular resistance (PVR) > 3 Wood units as confirmed by right heart catheterization. The prevalence and geographic distribution of PAH vary depending on the type and etiology of the disease. Despite enormous efforts in the research and development of therapeutic agents in the last twenty years, the disease remains relatively incurable and the overall prognosis remains guarded. Median survival for an untreated patient is 2.8 years. In the last three decades, there have been dramatic advances in understanding the molecular mechanisms and signaling pathways involved in the disease, resulting in emerging new treatment strategies. In the following pages, we will review currently approved treatments for PAH, as well as a new generation of investigational drugs.

引用

页码：460 / 473

页数：14

共 98 条

[1] Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats [J].

Abe, K ;

Shimokawa, H ;

Morikawa, K ;

Uwatoku, T ;

Oi, K ;

Matsumoto, Y ;

Hattori, T ;

Nakashima, Y ;

Kaibuchi, K ;

Sueishi, K ;

Takeshita, A .

CIRCULATION RESEARCH, 2004, 94 (03) :385-393

[2] Pulmonary Arterial Hypertension in the Southern Hemisphere Results From a Registry of Incident Brazilian Cases [J].

Alves, Jose Leonidas, Jr. ;

Gavilanes, Francisca ;

Jardim, Carlos ;

Cesar dos Santos Fernandes, Caio Julio ;

Kato Morinaga, Luciana Tamie ;

Dias, Bruno ;

Hoette, Susana ;

Humbert, Marc ;

Souza, Rogerio .

CHEST, 2015, 147 (02) :495-501

[3] ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension [J].

Badesch, David B. ;

Feldman, Jeremy ;

Keogh, Anne ;

Mathier, Michael A. ;

Oudiz, Ronald J. ;

Shapiro, Shelley ;

Farber, Harrison W. ;

McGoon, Michael ;

Frost, Adaani ;

Allard, Martine ;

Despain, Darrin ;

Dufton, Christopher ;

Rubin, Lewis J. .

CARDIOVASCULAR THERAPEUTICS, 2012, 30 (02) :93-99

[4] Diagnosis and Assessment of Pulmonary Arterial Hypertension [J].

Badesch, David B. ;

Champion, Hunter C. ;

Gomez Sanchez, Miguel Angel ;

Hoeper, Marius M. ;

Loyd, James E. ;

Manes, Alessandra ;

McGoon, Michael ;

Naeije, Robert ;

Olschewski, Horst ;

Oudiz, Ronald J. ;

Torbicki, Adam .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (01) :S55-S66

[5] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[6] Beraprost therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

McGoon, M ;

McLaughlin, V ;

Tapson, V ;

Oudiz, R ;

Shapiro, S ;

Robbins, IM ;

Channick, R ;

Badesch, D ;

Rayburn, BK ;

Flinchbaugh, R ;

Sigman, J ;

Arneson, C ;

Jeffs, R .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125

[7] An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry [J].

Benza, Raymond L. ;

Miller, Dave P. ;

Barst, Robyn J. ;

Badesch, David B. ;

Frost, Adaani E. ;

McGoon, Michael D. .

CHEST, 2012, 142 (02) :448-456

[8] Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension [J].

Benza, Raymond L. ;

Seeger, Werner ;

McLaughlin, Vallerie V. ;

Channick, Richard N. ;

Voswinckel, Robert ;

Tapson, Victor F. ;

Robbins, Ivan M. ;

Olschewski, Horst ;

Rubin, Lewis J. .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (12) :1327-1333

[9] The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted [J].

Bonnet, Sebastien ;

Rochefort, Gael ;

Sutendra, Gopinath ;

Archer, Stephen L. ;

Haromy, Alois ;

Webster, Linda ;

Hashimoto, Kyoko ;

Bonnet, Sandra N. ;

Michelakis, Evangelos D. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (27) :11418-11423

[10] An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats -: Similarities to human pulmonary arterial hypertension [J].

Bonnet, Sébastien ;

Michelakis, Evangelos D. ;

Porter, Christopher J. ;

Andrade-Navarro, Miguel A. ;

Thébaud, Bernard ;

Bonnet, Sandra ;

Haromy, Alois ;

Harry, Gwyneth ;

Moudgil, Rohit ;

McMurtry, Sean ;

Weir, E. Kenneth ;

Archer, Stephen L. .

CIRCULATION, 2006, 113 (22) :2630-2641

← 1 2 3 4 5 6 7 8 9 10 →